• Customer Login
  • Search
KindredBio
  • About
    • Background
    • Our Story
    • KindredBio Leadership
    • Board of Directors
  • Pipeline
    • Canine Pipeline
    • Clinical Trials
  • Products
    • Zimeta™ (dipyrone injection)
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Education
    • Continuing Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu
News
You are here: Home / News / Future Events / No Events Currently Scheduled

No Events Currently Scheduled

February 12, 2013/in Future Events /by Russell Radefeld
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/2017/09/KindredBioHeader2017.png 0 0 Russell Radefeld /wp-content/uploads/2017/09/KindredBioHeader2017.png Russell Radefeld2013-02-12 22:25:522016-02-12 22:27:50No Events Currently Scheduled

KindredBio News

  • Kindred Biosciences to Announce First Quarter 2021 Financial Results
  • Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication
  • Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study
  • Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results
  • Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial Results

News Archives

  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • August 2015
  • May 2015
  • March 2015
  • December 2014
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • December 2013
  • August 2013
  • July 2013
  • March 2013
  • February 2013
  • January 2013

News

  • Kindred Biosciences to Announce First Quarter 2021 Financial ResultsMay 3, 2021 - 9:04 am
  • Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy IndicationApril 28, 2021 - 8:40 am
  • Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK StudyApril 20, 2021 - 4:05 pm

Events

  • Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:48 am
  • Event: Kindred Biosciences to Present at the H.C. Wainwright Global Life Sciences ConferenceMarch 2, 2021 - 8:45 am
  • Event: Kindred Biosciences to Present at the Barclays Global Healthcare ConferenceMarch 2, 2021 - 8:43 am
$4.63 Stock is Up 0.01 (0.22%)
KIN (Common Stock)
Previous Close Volume
$4.62 292,202
Intraday High Intraday Low
$4.66 $4.55
52 Week High 52 Week Low
$6.00 $3.20
Exchange: NASDAQ CM
Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements
© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010
KindredBio Announces Filing of an Investigational New Animal Drug Application... KindredBio Announces the Filing of an INAD for Laminitis in Horses
Scroll to top